Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health to Occupational Risk Awareness

The Tileston Health Clinic has long served as a trusted source of general health information and primary care for underserved populations, emphasizing broad wellness and chronic disease management. This legacy of accessible health education naturally extends to understanding how common medications can carry significant long-term risks. In the context of mass production environments, workers may encounter sustained exposure to medications such as Reglan (metoclopramide), often prescribed off-label or as part of routine care for gastrointestinal issues. The transition from general health awareness to occupational exposure concern arises when considering that individuals in manufacturing or industrial settings may have prolonged or repeated contact with this drug, either through direct administration or environmental exposure. This shift in focus moves from population-level health guidance to a more specific concern: the potential for cumulative exposure in the workplace to contribute to adverse neurological outcomes. The bridge between general health literacy and occupational risk assessment requires acknowledging that medication safety profiles, while established for typical therapeutic use, may not fully account for the patterns of exposure found in mass production contexts. This perspective reframes the discussion from passive health information consumption to active risk evaluation in occupational settings.

Understanding Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is associated with a risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The warning also notes that Reglan is contraindicated in patients with a history of TD, and that treatment should be used for the shortest duration necessary, with periodic reassessment of the need for continued therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Similarly, in patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation of TD involves involuntary, repetitive movements, often of the face or tongue, and may also affect the trunk and extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). These movements can be disfiguring and are potentially irreversible. The prescribing information also warns that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms of TD occur, Reglan should be discontinued immediately, and medical attention sought (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Epidemiological Evidence and Risk Factors

Epidemiological data on the incidence of TD with oral metoclopramide use have been reassessed in recent studies. A real-world epidemiology study using the MarketScan Research database (2011-2020) analyzed TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing rates among metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to provide updated incidence estimates, as older studies reported inconsistent rates ranging from 1% to 15% (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another review of the literature, including PubMed and Google Scholar searches, found that the risk of TD from metoclopramide is low, in the range of 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines (https://pubmed.ncbi.nlm.nih.gov/31050085/). This review identified high-risk groups as elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/). From a mechanistic perspective, metoclopramide is a dopamine receptor antagonist, and chronic blockade of dopamine receptors in the basal ganglia is thought to contribute to the development of TD. The prescribing information advises avoiding concomitant use of other drugs known to cause TD, extrapyramidal symptoms (EPS), or neuroleptic malignant syndrome (NMS), and avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The boxed warning emphasizes that the risk of TD increases with duration of treatment and total cumulative dosage, highlighting the importance of limiting exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Settlement Valuation Factors for Reglan TD Claims

In the context of settlement considerations for affected patients, several factors are relevant. The adequacy of warnings regarding Reglan and TD is a key issue. The FDA-approved labeling includes a boxed warning that clearly states the risk of TD, its potential irreversibility, and the need for short-term use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, the extent to which prescribers and patients were adequately informed about this risk, particularly in the context of off-label or long-term use, may influence liability. The timeline between exposure and documented harm is also critical; TD may develop after months or years of metoclopramide use, and the risk is cumulative (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who developed TD after prolonged use beyond the recommended 12-week duration may have stronger claims, as the labeling explicitly advises against such use. Settlement valuation for TD claims often considers the severity and irreversibility of the movement disorder, the impact on quality of life, and the presence of risk factors such as advanced age, female sex, diabetes, or concurrent antipsychotic use (https://pubmed.ncbi.nlm.nih.gov/31050085/). The low absolute risk of TD (0.1% per 1000 patient-years) may be weighed against the severity of the condition in individual cases. Additionally, the availability of alternative treatments for gastroparesis, and whether Reglan was prescribed for an approved indication and duration, are relevant factors. The boxed warning's directive to use Reglan for the shortest duration and to periodically reassess the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397) underscores the importance of adherence to prescribing guidelines in mitigating risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the risk of tardive dyskinesia from Reglan?

The risk of tardive dyskinesia (TD) from Reglan is low, estimated at 0.1% per 1000 patient-years, according to a review of literature (https://pubmed.ncbi.nlm.nih.gov/31050085/). However, the condition can be severe and irreversible. Risk increases with longer treatment duration and higher cumulative dose, and is higher in elderly females, diabetics, and those on antipsychotics.

What factors affect the valuation of a Reglan TD claim?

Key factors include the adequacy of warnings, duration of Reglan use beyond the recommended 12 weeks, severity and irreversibility of TD, impact on quality of life, presence of risk factors (age, sex, diabetes, antipsychotic use), and whether the drug was prescribed for an approved indication. The FDA boxed warning emphasizes short-term use and monitoring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.